People: Tengion Inc (TNGN.PK)


TNGN.PK on OTC Markets Group

0.54USD
18 Jun 2013
Price Change (% chg)

$-0.01 (-1.82%)
Prev Close
$0.55
Open
$0.55
Day's High
$0.55
Day's Low
$0.54
Volume
5,650
Avg. Vol
6,045
52-wk High
$5.25
52-wk Low
$0.51

Search Stocks

Summary

Name Age Since Current Position

David Scheer

 60 2003 Independent Chairman of the Board

Timothy Bertram

 57 2011 President - Research and Development, Chief Scientific Officer

John Miclot

 53 2011 President, Chief Executive Officer, Director

A. Brian Davis

 46 2010 Chief Financial Officer, Vice President - Finance

Carl-Johan Dalsgaard

 55 2004 Independent Director

Diane Jorkasky

 60 2011 Independent Director

Richard Kuntz

 55 2010 Independent Director

Lorin Randall

 69 2008 Independent Director
» Insider Trading

Biographies

Name Description

David Scheer

 Mr. David I. Scheer is Independent Chairman of the Board of Tengion Inc. Since 1981, Mr. Scheer has served as President of Scheer & Company, Inc., a Company that provides venture capital, corporate strategy, and transactional advisory services focused on the life sciences. Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc., OraPharma, Inc. (acquired by Johnson and Johnson in 2003), and Esperion Therapeutics, Inc. (acquired by Pfizer in 2004). He currently serves as the chairman of the Board of Directors of Achillion Pharmaceuticals, Inc. and Aegerion Pharmaceuticals, Inc., both publicly traded biotechnology companies. From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and currently serves as Chair of “The Unfinished Agenda in Infectious Diseases,” an initiative at the Harvard School of Public Health focusing on neglected diseases. He has also been a member of the Board of Trustees, and most recently Vice-Chair for the Long Wharf Theatre, in New Haven, Connecticut. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.

Timothy Bertram

 Dr. Timothy Bertram, DVM, Ph.D., is President - Research and Development, Chief Scientific Officer of Tengion Inc. Dr. Bertram is responsible for research and development efforts. Prior to the Company, Dr. Bertram served as a senior scientific executive at Pfizer, multi-national pharmaceutical Company, from 1999 to 2004, and held a similar position at SmithKline Beecham Pharmaceuticals, multi-national pharmaceutical and healthcare Company, from 1996 to 1999, and Procter & Gamble Co., multi-national Company that manufactures consumer goods, from 1989 to 1996. He was a faculty member at the University of Illinois from 1984 to 1987 and was a visiting scientist to the National Institutes of Health from 1987 to 1989. Dr. Bertram received a D.V.M. and Ph.D. from Iowa State University and completed post-doctoral studies in cell signaling pathways.

John Miclot

 Mr. John L. Miclot is President, Chief Executive Officer, Director of Tengion Inc. Prior to joining Company, Mr. Miclot was an Executive-in-Residence at Warburg Pincus from March 2010 to March 2011. He was President and Chief Executive Officer of CCS Medical, Inc., a company owned by Warburg Pincus and a provider of products and services for patients with chronic diseases, from November 2008 until completion of a financial restructuring of the Company in March 2010. From 2003 to 2008, Mr. Miclot served as President and Chief Executive Officer of Respironics, Inc. until the sale of the Respironics to Royal Philips. Mr. Miclot served as Chief Executive Officer of Philips Home Healthcare Solutions following the acquisition of Respironics, Inc. by Royal Philips. Mr. Miclot spent 10 years in senior roles at Respironics, ultimately serving as President and Chief Executive Officer from 2003 to 2008. Mr. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies, Inc., a medical device Company. Mr. Miclot served as the Senior Vice President of Sales and Marketing Healthdyne from 1995 to 1998. Earlier in his career, he held sales and marketing roles at Medex, Ohmeda, Baxter Edwards, and DeRoyal Industries. Mr. Miclot is a director of Wright Medical Group, Inc., Dentsply International Inc., and Body Media and serves as Chairman of the Board of Directors of Breathe Technologies, Inc. He is also a director of the Pittsburgh Zoo & PPG Aquarium and Burger King Cancer Caring Center. He earned his B.B.A. in marketing from the University of Iowa.

A. Brian Davis

 Mr. A. Brian Davis is Chief Financial Officer, Vice President - Finance of Tengion Inc. From April 2009 to July 2010, Mr. Davis served in a consulting capacity as Chief Financial Officer of Neose Technologies, Inc. From 1994 to April 2009, Mr. Davis was employed by Neose Technologies, Inc., a biopharmaceutical company focused on the development of next-generation therapeutic proteins, where he served most recently as Senior Vice President and Chief Financial Officer. From 1991 to 1994, Mr. Davis was employed by MICRO HealthSystems, Inc., a provider of healthcare information systems, where he served most recently as Corporate Controller. Mr. Davis is licensed as a Certified Public Accountant, received his B.S. in accounting from Trenton State College and his MBA from the Wharton School of the University of Pennsylvania.

Carl-Johan Dalsgaard

 Dr. Carl-Johan Dalsgaard, M.D., Ph.D., is Independent Director of Tengion Inc. Dr. Dalsgaard has also been a member of HealthCap IV GP SA, L.L.C. (HCSA) and HealthCap IV GP AB, L.L.C. (HCAB and, collectively with HCSA, HealthCap), a venture capital fund that invests globally in pharmaceutical, biotechnology and medical technology companies from June 2000 to the present and serves as Chief Executive Officer of certain companies in which HealthCap has invested. He received an M.D. from the Karolinska Institute in Sweden, and a Ph.D. in neurobiology and post-doctoral experience from Harvard Medical School. Dr. Dalsgaard has fulfilled specialist training for a board certificate in plastic and reconstructive surgery at Karolinska Hospital.

Diane Jorkasky

 Dr. Diane K. Jorkasky, M.D., is Independent Director of Tengion, Inc. Dr. Jorkasky has been an independent consultant since February 2012. From August 2011 to February 2012, she served as the enterprise-wide Chief Medical Officer of Endo Pharmaceuticals, Inc., or Endo, and a member of Endo’s senior R&D management team. Prior to joining Endo, Dr. Jorkasky served as an independent consultant from January 2011 to August 2011, and was the Senior Vice President, Chief Development and Medical Officer at Aileron Therapeutics, Inc. from September 2009 to January 2011. Dr. Jorkasky also held vice president level positions from October 2000 to January 2009 with Pfizer, Inc. where she led global clinical research science and operational groups, most recently as Vice President, Worldwide Clinical Research Operations.

Richard Kuntz

 Dr. Richard E. Kuntz, M.D., M.Sc., is Independent Director of Tengion Inc. Dr. Kuntz has served as the Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of Medtronic, Inc. since August 2009, prior to which time he served as the Senior Vice President and President, Neuromodulation from October 2005 to August 2009. In his current role, role Dr. Kuntz oversees Medtronic’s global regulatory affairs, health policy and reimbursement, clinical research activities, ventures and new therapies, strategy and innovation, corporate development, and acquisitions, integrations and divestitures functions. Dr. Kuntz brings a broad background and in many different areas of healthcare. Prior to Medtronic, he was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the United States Food and Drug Administration (FDA). Dr. Kuntz has directed over 100 multicenter clinical trials and has authored more than 200 original publications. Dr. Kuntz also served as Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston, MA. Dr. Kuntz graduated from Miami University and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency in internal medicine at the University of Texas Southwestern Medical School, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Dr. Kuntz received his master’s of science in biostatistics from the Harvard School of Public Health.

Lorin Randall

 Mr. Lorin Jeffry Randall is Independent Director of Tengion Inc. Mr. Randall has been an independent financial consultant since May 2006. Previously, Mr. Randall was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development Company, from December 2004 to May 2006. From 2002 to 2004, Mr. Randall served as the Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. He currently serves on the boards of directors of Nanosphere, Inc., Athersys, Inc. and Acorda Therapeutics, Inc. Mr. Randall served on the Board of Directors of Opexa Therapeutics, Inc., a publicly-traded cellular therapy company, from 2007 to 2009. Mr. Randall received a BS in accounting from The Pennsylvania State University and an MBA from Northeastern University.

Basic Compensation

Name Fiscal Year Total

David Scheer

 --

Timothy Bertram

 676,902

John Miclot

 1,137,500

A. Brian Davis

 500,361

Carl-Johan Dalsgaard

 --

Diane Jorkasky

 --

Richard Kuntz

 --

Lorin Randall

 --
As Of 30 Dec 2012

Options Compensation

Name Options Value

David Scheer

 0 0

Timothy Bertram

 0 0

John Miclot

 0 0

A. Brian Davis

 0 0

Carl-Johan Dalsgaard

 0 0

Diane Jorkasky

 0 0

Richard Kuntz

 0 0

Lorin Randall

 0 0

Insider Trading

Name Shares Traded Price

MICLOT JOHN L

 2,913 $1.25

BERTRAM TIMOTHY

 1,217 $1.25

DAVIS A BRIAN

 179 $1.25

BERTRAM TIMOTHY

 325 $1.25

DAVIS A BRIAN

 523 $1.25

DAVIS A BRIAN

 68,333 $0.00

BERTRAM TIMOTHY

 150,000 $0.00

MICLOT JOHN L

 393,750 $0.00
» Full list on Insider Trading
Search Stocks